Orchestra BioMed Holdings (OBIO) Cash from Operations (2021 - 2026)
Orchestra BioMed Holdings (OBIO) posted quarterly Cash from Operations of 22168000.0 for Q1 2026, down 33.41% year-over-year from 33292072.31 in Q1 2025, and down 876.56% quarter-over-quarter from 2270000.0 in Q4 2025.
Powered by 
Analysis
Orchestra BioMed Holdings (OBIO) Cash from Operations (2021 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has reported Cash from Operations for 6 consecutive years, with 22168000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations fell 33.41% year-over-year to 22168000.0; the TTM figure through Mar 2026 stood at 54515000.0 (down 0.84% YoY), while the FY2025 annual figure was 48963000.0, up 3.15% from the prior year.
- Cash from Operations retreated to 22168000.0 in Q1 2026 per OBIO's latest filing, from 2270000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 2270000.0 in Q4 2025 and bottomed at 22168000.0 in Q1 2026.
- Historically, Cash from Operations has averaged 11594411.76 across 5 years, with a median of 10974000.0 in 2023.
- Annual changes were most pronounced in 2022 — Cash from Operations tumbled 30224.26% — and 2025, when it soared 83.23%.
- Orchestra BioMed Holdings' Cash from Operations stood at 8744000.0 in 2022, then fell by 25.5% to 10974000.0 in 2023, then slipped by 23.36% to 13538000.0 in 2024, then jumped by 83.23% to 2270000.0 in 2025, then tumbled by 876.56% to 22168000.0 in 2026.
- Business Quant data shows OBIO's Cash from Operations at 22168000.0 in Q1 2026, 2270000.0 in Q4 2025, and 14550000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Orchestra BioMed Holdings | 322.25 Mn | 127.72 Mn | 63,000.00 | -19.33 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -19.33 Mn |
| Mar 31, 2026 | -22.17 Mn |
| Dec 31, 2025 | -2.27 Mn |
| Sep 30, 2025 | -14.55 Mn |
| Jun 30, 2025 | -15.53 Mn |
| Mar 31, 2025 | -16.62 Mn |
| Dec 31, 2024 | -13.54 Mn |
| Sep 30, 2024 | -13.70 Mn |
| Jun 30, 2024 | -10.21 Mn |
| Mar 31, 2024 | -13.11 Mn |
| Dec 31, 2023 | -10.97 Mn |
| Sep 30, 2023 | -10.28 Mn |
| Jun 30, 2023 | -10.49 Mn |
| Mar 31, 2023 | -14.38 Mn |
| Dec 31, 2022 | -8.74 Mn |
| Sep 30, 2022 | -7.26 Mn |
| Jun 30, 2022 | -7.97 Mn |
| Mar 31, 2022 | -5.32 Mn |
| Dec 31, 2021 | -28,835.00 |
| Sep 30, 2021 | -128,010.00 |